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Abstract 
Malignant giant cell tumor (GCT) of bone is
a rare tumor with debilitating consequences.
Patients  with  GCT  of  bone  typically  present
with mechanical difficulty and pain as a result
of bone destruction and are at an increased
risk for fracture. Because of its unusual occur-
rence, little is known about the epidemiology
of malignant GCT of bone. This report offers
the first reliable population-based estimates of
incidence,  patient  demographics,  treatment
course and survival for malignancy in GCT of
bone in the United States. Using data from the
National  Cancer  Institute’s  Surveillance,
Epidemiology  and  End  Results  (SEER)  pro-
gram, we estimated the overall incidence and
determinants of survival among patients diag-
nosed with malignant GCT of bone from 1975-
2004. Cox proportional hazards regression was
used  to  evaluate  demographic  and  clinical
determinants  of  survival  among  malignant
GCT cases. Based on analyses of 117 malig-
nant  GCT  cases,  the  estimated  annual  inci-
dence  in  the  United  States  was  1.6  per
10,000,000  persons  per  year.  Incidence  was
highest among adults aged 20 to 44 years (2.4
per  10,000,000  per  year)  and  most  patients
were  diagnosed  with  localized  (31.6%)  or
regional (29.9%) disease compared to distant
disease  (16.2%).  Approximately  85%  of
patients survived at least 5 years, with survival
poorest among older patients and those with
evidence of distant metastases at time of diag-
nosis. The current study represents the largest
systematic investigation examining the occur-
rence and distribution of malignancy in GCT of
bone in the general U.S. population. We con-
firm its rare occurrence and suggest that age
and stage at diagnosis are strongly associated
with long-term survival.  
Introduction
Giant  cell  tumors  (GCTs)  of  bone  occur
infrequently,  comprising  just  5%  of  all  bone
tumors,  both  benign  and  malignant.
1
However, the disease can be incapacitating, as
patients  with  GCT  of  bone  typically  present
with mechanical difficulty and pain resulting
from bone destruction and are at an increased
risk for fracture.
1-3 GCTs are observed predom-
inantly at the ends of long bones, most com-
monly located in and around the knee (distal
femur,  proximal  tibia)  and  wrist  (distal
radius).
1 They are categorized according to the
Enneking staging system, where the patholog-
ic spectrum ranges from static and confined to
the bone (Stage 1) to aggressive, extending
into the surrounding soft tissue (Stage 3).
4 A
radiographic  grading  system  developed  by
Campanacci et al. grades lesions from 1 to 3,
with Grade 1 lesions having well-defined mar-
gins and an intact cortex, and Grade 3 having
irregular  margins  and  cortical  destruction.
5
Metastases can develop from both benign and
malignant GCTs; and lung is the most frequent
metastatic site.
6
Histologically,  GCTs  are  a  heterogeneous
mix of multinucleated giant cells resembling
osteoclasts,  spindle-shaped  stromal  cells
exhibiting  features  of  osteoblast  precursors
and CD-68 positive mononuclear cells.
7,8 The
neoplastic cell of origin has not been identified
conclusively. Recently, expression of the ligand
for  receptor  activator  of  nuclear  factor  κB
(RANKL), a factor critical in the development
and activation of osteoclasts, was detected in
GCT, raising the possibility of controlling bone
lysis  from  GCT  by  inhibition  of  the  RANKL-
RANK axis.
9
While GCTs account for approximately 20%
of  all  benign  bone  tumors,
1 malignancies  in
GCT of bone are much rarer and are typically
classified as primary or secondary according to
specific criteria.
10,11 A primary malignant GCT
of bone will most often arise concurrently and
closely with a benign tumor; however, sponta-
neous neoplasm may occur in the absence of
benign growth.  Secondary malignant GCTs are
more common than primary malignant GCTs
and  arise  after  treatment  of  a  previously
benign  tumor  and  more  often  in  patients
undergoing radiation therapy with or without
curettage.
6 While GCT is typically associated
with a favorable prognosis, the long-term prog-
nosis for malignant transformation of a previ-
ously benign-appearing tumor is poor. Further,
reports.
3,11-13 indicate that those patients with a
history of radiation treatment for benign GCT
tend to have poorest outcomes, suggesting that
rigorous  follow-up  of  patients  treated  for
benign tumors even decades after initial diag-
noses is crucial to insuring long-term survival.
Because of the rarity of the malignant vari-
ety,  there  are  limited  sources  which  can  be
used to characterize incidence and survival fol-
lowing a diagnosis of malignancy in GCT of
bone.  Most published data on its epidemiology
have  been  generated  from  hospital-based
patient series, which may not accurately trans-
late to the larger population in terms of patient
and  tumor  characteristics  and  frequency  of
occurrence in the general population.
To  better  understand  the  epidemiology  of
malignancy in GCT of bone, we consulted data
from  the  National  Cancer  Institute’s  (NCI)
Surveillance,  Epidemiology  and  End  Results
(SEER) Program, which represents the most
comprehensive and complete source of infor-
mation available on the diagnosis, demograph-
ics, treatment and follow-up of cancer patients
in  the  United  States  (U.S.).
14 To  our  knowl-
edge, this study represents the first systematic
U.S. investigation of the descriptive epidemiol-
ogy of this rare tumor using a large, popula-
tion-based dataset. 
Materials and Methods
Surveillance, Epidemiology and End
Results registry and study population
We  used  data  gathered  as  part  of  the
National  Cancer  Institute’s  SEER  Program.
SEER currently consists of 18 statewide and
regional  tumor  registries  spread  throughout
the U.S., covering approximately 26% of the
population  (http://seer.cancer.gov/registries/
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data.html). The individual registries are geo-
graphically  located  to  over-sample  minority
populations,  including  African  Americans,
Hispanics, Asian Pacific Islanders, and Native
Americans.  SEER  routinely  collects  data  on
patient demographics (age at diagnosis, gen-
der, race/ethnicity and geographic residence at
the time of diagnosis), tumor characteristics
(size, grade, stage), first course of treatment,
as well as follow-up documentation of vital sta-
tus (date and cause of death). Based on the
rare occurrence of malignancy in GCT of bone,
coupled with our initial goal of assessing epi-
demiologic time trends, we limited our analy-
ses  to  the  longest  running  SEER  registries
(Connecticut,  Detroit,  Hawaii,  Iowa,  New
Mexico, San Francisco-Oakland, Utah, Seattle-
Puget Sound, and Atlanta), all of which have
collected  information  on  invasive  cancers
diagnosed from 1975 through 2004 and repre-
sent  nearly  10%  of  the  U.S.  population.
Patients  included  in  the  current  study  were
those  diagnosed  with  malignant  giant  cell
tumors of bone (ICD-O-3 codes, M-9250/1, M-
9250/3,  M-8003/3,  and  primary  site  codes
C40.0-C41.9)  between  January  1,  1975  and
December 31, 2004. Classification of tumors
was based upon SEER summary staging crite-
ria.  SEER summary stage is produced using
the extent of disease information from medical
records and pathology reports reviewed at the
time of diagnosis. A localized tumor is defined
as an invasive neoplasm a.) confined to the
cortex of the bone; or b.) extends beyond the
cortex into the periosteum (with no break in
the periosteum). Regional stage is defined as
a neoplasm that has a.) extended beyond the
periosteum  into  adjacent  bone,  cartilage  or
skeletal  muscle;  or  b.)  into  regional  lymph
nodes by way of the lymphatic system; or c.) a
combination of extension and regional lymph
node  involvement.  A  distant  classification
would include a neoplasm that has spread to
parts  of  the  body  remote  from  the  primary
tumor either by direct extension or by metasta-
sis  to  distant  organs,  tissues  or  the  distant
lymph  nodes  via  the  lymphatic  system
(http://seer.cancer.gov/tools/ssm/muscu-
loskel.pdf).  
Statistical methods
Patient (age at diagnosis, gender, race/eth-
nicity), tumor (stage), and treatment (receipt
of  surgery  and/or  radiation)  characteristics
were  described  for  all  individuals  diagnosed
with malignant GCT of bone across the study
period  (1975-2004).    Annual  crude  and  age-
adjusted incidence rates per 10,000,000 per-
sons were calculated using SEER*Stat v. 6.36
and then averaged over the entire study period
and for 5-year periods using U.S. county popu-
lation estimates. Estimates were age-adjusted
using the 2000 U.S. population as the standard
population. Chi-square tests were conducted to
determine  differences  in  incidence  rates
across the study period by age at diagnosis,
gender,  race/ethnicity  (white,  black,  other
race)  and  SEER  summary  stage  (localized,
regional, distant).
SEER*Stat was also used to calculate rela-
tive survival rates for the entire study cohort.
SAS software version 9.1 (SAS Institute, Cary,
N.C., USA) was used to build Cox proportional
hazards (PH) regression models to estimate
the relation of select factors and survival fol-
lowing a diagnosis of malignant GCT of bone.
Individuals were censored at the date of death,
the date last known to be alive (if lost to follow-
up), or December 31, 2004, whichever came
first. Variables included in the final Cox PH
model were: age at diagnosis (in 5-year age
groups), year of diagnosis, gender, race, stage
at diagnosis, and receipt of first-line treatment
(none, surgery, radiation, or a combination of
surgery and radiation).  
Results
From 1975 through 2004, a total of 117 indi-
viduals were identified as having been diag-
nosed with “primary” malignant GCT of bone
in  the  SEER  9  registry  regions  (Table  1).
“Primary”  in  this  context  means  that  the
tumor is the first and/or only invasive cancer
diagnosed, not to be confused with the afore-
mentioned definitions of primary versus sec-
ondary malignancy in GCT. Most patients diag-
nosed  were  between  the  ages  of  20  and  44
years  (57.3%),  female  (53.9%),  and  white
(74.4%).  Of  these  patients,  nearly  one-third
(31.6%) were diagnosed with disease confined
to the bone, 29.9% were diagnosed with cancer
with evidence of extension into the surround-
ing soft tissue, 16% were diagnosed with dis-
tant  metastasis,  and  22%  were  of  unknown
stage. The primary treatment for most patients
(69.3%)  was  surgical  removal  of  the  tumor
either with (12.0%) or without (57.3%) radia-
tion therapy. First-line treatment was associat-
ed with stage at diagnosis; as most patients
with localized disease received surgery where-
as  patients  with  more  advanced  disease
received  radiation  therapy  (with  or  without
surgery) as primary treatment (P<0.0001). 
The  incidence  of  malignant  GCT  of  bone
was  extremely  low  for  the  thirty-year  study
period (1.6 per 10,000,000 persons per year)
(Table  2).  As  one  of  the  initial  aims  of  the
investigation was to examine trends in occur-
rence over time, incidence was estimated for
5-year time periods.  However, because of the
small  number  of  cancers  reported  for  each
time period, no formal tests of trend over time
were conducted. Annual incidence estimates
varied  from  1.0  per  10,000,000  in  the  most
recent  time  period  (2000-2004)  to  2.2  per
10,000,000  persons  (in  1975-1979  and  1985-
1989).  The  average  annual  malignant  GCT
incidence across the entire study period did
not differ significantly by gender or race/eth-
nicity. However, the annual incidence did dif-
fer depending upon age, with the highest inci-
dence  observed  among  those  aged  20  to  44
years (2.4 per 10,000,000 persons), with esti-
mates ranging from 1.6 in 2000-2004 to 3.2 in
1975-1979 across the study period.  Metastatic
GCT  of  bone  was  exceedingly  rare;  its  inci-
dence was lower than that of either localized or
regional disease (P=0.04). 
The mean survival time for patients diag-
nosed  with  malignant  GCT  of  bone  was  11
years and 11 months, with a 5-year relative
survival of 84.2%.  As would be expected, Cox
proportional hazards modeling indicated that
older age and more advanced stage at time of
diagnosis were associated with an increased
risk of death after controlling for other poten-
tial  important  determinants  (Table  3).  More
specifically, for each 5-year increase in age at
diagnosis, the risk of death increased by 41%
(P<0.0001). Likewise, for patients with distant
metastases detected at the time of diagnosis,
Article
Table  1.  Characteristics  of  patients  diag-
nosed  with  malignant    giant  cell  tumors
(GCT)  of  bone  (SEER†  1975-2004)
(N=117).
Characteristic N (%)
Age at diagnosis
<20 years 12 (10.2)
20-44 years 67 (57.3)
45+ years 38 (32.5)
Gender
Female 63(53.9)
Male 54(46.1)
Race
White 87 (74.4)
Black 14 (12.0)
Other 16 (13.6)
Stage at diagnosis
Localized 37(31.6)
Regional  35(29.9)
Distant  19 (16.2)
Treatment
Surgery only 67 (57.3)
Surgery + radiation 14 (12.0)
Radiation only 15 (12.8)
None 15 (12.8)
Unknown    6 (5.1)
SEER Region at diagnosis
Detroit, MI 24 (20.5)
Connecticut 23 (19.7)
San Francisco-Oakland, CA 21 (17.9)
Seattle-Puget Sound, WA 15 (12.8)
Hawaii 9  (7.6)
New Mexico 7  (6.0)
Atlanta, GA 6  (5.2)
Iowa 5  (4.3)
Utah 7  (6.0)[Rare Tumors 2009; 1:e52] [page 161]
the risk of death was 5.2 times higher com-
pared to those diagnosed with tumor confined
to the bone (P=0.007). However, there was no
significant difference in risk of death between
patients  with  regional  and  localized  disease
(P=0.49).  Year  of  diagnosis,  gender  and
race/ethnicity were not significantly related to
survival.
Discussion
To our knowledge, this represents the first
investigation  of  malignancy  in  GCT  of  bone
conducted in the general U.S. population.  Our
results confirm that malignant GCT of bone is
a rare occurrence in the United States (less
than one case per million persons per year).
While  we  observed  a  decrease  in  incidence
over the decades from 2.2 cases per 10 million
persons in the 1970’s to 1.0 case per 10 million
persons in the 2000’s, the rarity of the tumor
prevented any formal test of trend in incidence
over time. Results reported in an analysis of 75
malignant GCT of bone cases from a Swedish
population-based  national  cancer  registry
showed an average annual incidence of 0.63
per  million  from  1958  to  1968,  a  somewhat
higher  estimate  than  our  own.
15 However,
based on the small number of cases identified
in  both  the  Swedish  report  and  our  current
investigation, it is possible that the observed
trends in incidence over time and/or difference
in incidence rates between these reports may
not be meaningful but merely a reflection of
chance variability in the populations studied.      
The current investigation is also the first to
examine racial/ethnic differences in the inci-
dence and survival associated with this rare
disease.  Our  results  suggest  no  significant
racial difference in the incidence of malignant
GCT  of  bone.  Survival  estimates  suggest  a
reduction in risk of death among non-white
compared with white patients, but the results
were not statistically significant.  And although
a  slightly  greater  proportion  of  cases  diag-
nosed were females compared to males, there
was  no  significant  difference  in  the  overall
incidence of malignant GCT by gender.  We
found most malignant GCT cases are typically
diagnosed in the third and fourth decades of
life,  a  finding  supported  by  most  case-
series.
2,3,5,16-19
The average 5-year relative survival rate for
patients with malignant GCT of the bone in our
study was 84.2%. As seen with other cancer
types, older age and metastatic disease at diag-
nosis  were  associated  with  poorer  survival.
However, we did not observe any significant
difference  in  risk  of  death  among  patients
diagnosed  with  regionally  advanced  disease.
No  significant  differences  in  risk  of  death
were  detected  by  year  of  diagnosis,  gender,
race,  or  treatment.  Our  survival  rates  are
improved  over  hospital-based  case-series  in
malignant GCT, possibly reflecting advances in
treatment  of  these  tumors  over  time  and/or
geographic differences in referral patterns to
specific institutions as well as availability and
access  to  medical  care  for  these  patients.
However, these are difficult theories to prove
with existing data. The SEER registry records
information on first line treatment, but no sub-
sequent treatment information is collected on
patients. Anract et al. observed a 5-year rela-
tive survival rate of 50% in a case-series of 29
malignant  GCT  patients  diagnosed  between
1954  and  1993.
3 Case  ascertainment  in  this
study began approximately twenty years prior
to the establishment of the SEER registry and
ended a decade prior to our patient follow-up.
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Table 2. Incidence of malignant GCTs of bone (in 5-year intervals), 1975-2004, accord-
ing to age at diagnosis, gender, race and stage.
Incidence per 10,000,000 persons
1975-2004 1975-79 1980-84 1985-89 1990-94 1995-99 2000-04
Overall 1.6 2.2 1.4 2.2 2.1 1.2 1.0
Age(years)
<20  0.6 1.6 -- 1.0 0.3 0.3 0.3
20-44  2.4 3.2 2.3 2.9 2.2 2.2 1.6
45+  1.7 1.7 1.2 2.4 3.6 0.5 1.0
p† <0.01
Gender
Male 1.5 2.0 1.1 2.1 1.8 1.1 1.3
Female 1.7 2.4 1.6 2.4 2.4 1.2 0.7
p 0.53
Race
White 1.5 2.4 1.4 2.1 1.9 0.9 0.9
Black 1.8 -- 3.4 2.9 0.2 1.8
Other 2.5 3.2 2.6 2.6 3.5 2.2 1.3
p 0.17
Stage
Localized 0.5 0.8 0.3 0.9 0.5 0.5 0.3
Regional 0.5 0.9 0.5 0.2 0.8 0.3 0.2
Distant 0.3 0.3 0.1 0.3 0.3 0.2 0.4
p 0.04
†
Corresponding p of χ
2 test to detect difference in incidence rates for period (1975-2004) between age, gender, race and stage groupings.
Table 3. The association between patient, treatment and tumor characteristics and risk of
death after diagnosis of malignant GCT of bone using Cox proportional hazards regres-
sion.
Characteristic Hazard ratio
† p
Age at diagnosis
‡ 1.41 <0.01
Year of diagnosis 1.03 0.84
Gender
Female 1.00
Male 0.73 0.46
Race
White 1.00
Black 0.45 0.17
Other 0.55 0.41
Stage at diagnosis
Localized 1.00
Regional spread 1.41 0.49
Distant metastases 5.20 <0.01
Stage unknown 0.20 0.14
Treatment 
None 1.00
Surgery  0.99 0.15
Radiation 0.76 0.69
Surgery + radiation 1.04 0.94
†Estimate of relative risk adjusted for all other variables in the final multivariable model (age, year of diagnosis, gender, race, stage, treat-
ment). 
‡Hazard Ratio represents an estimate of the increase in risk of death with each increase from one 5-year age group to the next
starting with and including the following age groupings (10-14 years, 15-19 years, …,>85 years)[page 162] [Rare Tumors 2009; 1:e52]
Bertoni et al. showed that 59% of all patients
diagnosed with malignancy in GCT at a single
institution eventually died, most of metastatic
disease.
12 The authors also indicated a survival
disparity between patients diagnosed with pri-
mary  and  secondary  malignant  GCT,  though
not formally tested because of the small num-
ber of patients in the series (n=17). Of notable
importance, there was variability in the num-
ber of patients diagnosed with primary versus
secondary malignant GCT in these studies as
less than one-third of patients included in the
Italian  study
12 were  diagnosed  with  primary
malignant GCT, while nearly 60% of patients in
the French investigation were similarly diag-
nosed.
3 A limitation of SEER with respect to
this  investigation  is  the  inability  to  classify
patients as having primary or secondary malig-
nant  GCT,  as  the  SEER  database  does  not
record medical history of benign lesions.  This
information  might  have  been  useful  in  our
evaluation  of  patient  survival.  If  survival  is
improved among patients diagnosed with pri-
mary  malignant  GCT  and  the  proportion  of
patients diagnosed with primary versus sec-
ondary  malignant  GCT  is  higher  among
patients in SEER, this might explain some of
the variability in survival rates between stud-
ies. As our study demonstrates, surgery is the
preferred treatment choice for most patients,
particularly if the tumor appears indolent and
confined to the bone.  For biologically aggres-
sive or recurrent tumors, curettage has been
coupled with adjuvant chemotherapy or radia-
tion.
6 The typical treatment for patients with
non-resectable GCT has been a course of mod-
erate-dose radiation therapy.
20,21 Reported rates
of recurrence of benign, primary malignancy
in GCT or secondary malignancy in GCT are
variable and dependent on tumor characteris-
tics and treatment.
1,22 Wide resection and the
adjuvant use of polymethymethacrylate follow-
ing intralesional curettage have been associat-
ed with reduced recurrence rates.
23,24 The use
of intravenous and oral bisphosphonates may
also reduce risk of local recurrence in patients
with soft tissue extension of GCT.
25
The treatment of recurrent and metastatic
GCT has been mostly surgical. Metastasectomy
of lung nodules may result in long-term sur-
vival.
26-28 Chemotherapy is generally of margin-
al benefit in advanced GCT, but may provide
palliative  treatment  of  primary  or  secondary
malignancy in GCT. Results of a phase II trial
of  the  fully  human  monoclonal  antibody  to
RANKL, denosumab, in patients with recurrent
or unresectable giant cell tumor of bone indi-
cate  nearly  90%  of  cases  had  a  positive
response to the agent (either elimination of
giant cells or no radiographic progression of
the target lesion) and nearly 85% of patients
reported reduced pain and/or improvement in
functional status,
29 suggesting that denosumab
is  a  viable  treatment  approach  for  patients
with advanced or metastatic GCT not amenable
to surgery.
Our investigation does have a few limita-
tions which necessitate some caution in eval-
uating our results. As previously mentioned,
our sample size prohibits the detection of sta-
tistically significant differences in incidence
across the study period and determinants of
long term survival amonng various subgroups.
Therefore, analyses relating demographic dif-
ferences in malignant GCT incidence as well
as demographic and clinical determinants of
survival  must  be  interpreted  with  prudence,
particularly if the observed disparities between
these  subsets  of  the  population  are  modest.
Additionally, formal review of the histopatholo-
gy of patients in this investigation was not pos-
sible because of the unavailability of historical
medical  records  on  all  patients  through  the
individual SEER registries. 
Nevertheless, the current investigation rep-
resents the largest population-based and most
comprehensive examination of the descriptive
epidemiology  of  malignancy  in  GCT  of  bone
and  the  first  of  its  kind  conducted  in  the
United  States.  Based  on  the  rare  nature  of
malignancy in GCT, only a large cancer data-
base  such  as  NCI’s  SEER  has  the  ability  to
accrue an adequate number of cases to esti-
mate rates of incidence and survival. An impor-
tant strength of the SEER cancer registry is the
active tracking of cases for vital status (over
97%) regardless of migration out of the reg-
istries catchment areas. Because losses to fol-
low-up in our patient population are minimal,
the calculated survival rates are an accurate
representation  of  the  survival  experience  of
these patients. In the future, we would recom-
mend that the SEER registries consistently and
routinely  collect  information  on  cases  of
benign GCT of bone as well. Benign GCT of
bone is unique in that it is considered to be a
borderline neoplasm because of its potential to
metastasize.  Obtaining  information  on  the
diagnosis,  treatment  and  follow-up  of  both
benign  and  malignant  GCT  cases  would
enhance  our  understanding  of  the  determi-
nants of risk and survival among those diag-
nosed with this disease.
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